Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / COM
-
Number of holders
-
74
-
Total 13F shares, excl. options
-
27.6M
-
Shares change
-
+492K
-
Total reported value, excl. options
-
$57.8M
-
Value change
-
+$1.54M
-
Put/Call ratio
-
0.23
-
Number of buys
-
33
-
Number of sells
-
-37
-
Price
-
$2.09
Significant Holders of Jade Biosciences, Inc. - COM (AVTE) as of Q3 2024
103 filings reported holding AVTE - Jade Biosciences, Inc. - COM as of Q3 2024.
Jade Biosciences, Inc. - COM (AVTE) has 74 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 27.6M shares
.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (9.19M shares), Sofinnova Investments, Inc. (3.76M shares), TCG Crossover Management, LLC (2.24M shares), Atlas Venture Life Science Advisors, LLC (1.8M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (1.41M shares), VANGUARD GROUP INC (1.15M shares), BlackRock, Inc. (954K shares), BAKER BROS. ADVISORS LP (629K shares), Affinity Asset Advisors, LLC (600K shares), and Eversept Partners, LP (485K shares).
This table shows the top 74 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.